Cargando…
The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines
Verdinexor (KPT‐335) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) compound that inhibits the function of the nuclear export protein Exportin 1 (XPO1/CRM1). In the present study, we sought to characterize the expression of XPO1 in primary canine osteosarcoma (OS) tumour...
Autores principales: | Breitbach, Justin T., Louke, Darian S., Tobin, Savannah J., Watts, Mauria R., Davies, Alexander E., Fenger, Joelle M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248106/ https://www.ncbi.nlm.nih.gov/pubmed/33438820 http://dx.doi.org/10.1111/vco.12680 |
Ejemplares similares
-
Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
por: Sadowski, Abbey R., et al.
Publicado: (2018) -
Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines
por: Korec, Daniela I., et al.
Publicado: (2021) -
Characterization of WWOX expression and function in canine mast cell tumors and malignant mast cell lines
por: Makii, Rebecca, et al.
Publicado: (2020) -
Plasma Cytokeratin 18 and fecal Alpha‐1 Antitrypsin concentrations in dogs with osteosarcoma receiving carboplatin chemotherapy
por: Taikowski, Kathryn, et al.
Publicado: (2020) -
Selective inhibitors of nuclear export (SINE) in hematological malignancies
por: Das, Arundhati, et al.
Publicado: (2015)